Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties

被引:30
作者
Damschroder, Melissa M.
Widjaja, Lusiana
Gill, Parkash S.
Krasnoperov, Valery
Jiang, Weidong
Dall'Acqua, William F.
Wu, Herren
机构
[1] Medimmune Inc, Dept Antibody Discovery & Prot Engn, Gaithersburg, MD 20878 USA
[2] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA
[3] Vasgene Therapeut Inc, Los Angeles, CA 90033 USA
关键词
antibody; humanization; affinity; thermostability; expression; isoelectric point;
D O I
10.1016/j.molimm.2006.12.019
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We report here the humanization of two mouse monoclonal antibodies (mAb) using framework shuffling of human germline genes. mAbs EA2 and 47 were raised against the human receptor tyrosine kinase EphA2 and EphB4, respectively, which exhibit increased expression levels in many cancer cell lines. One- and two-step strategies were carried out, in which the light and heavy chains of each parental mAb were simultaneously or sequentially humanized. We characterized in detail these newly humanized antibodies in terms of binding affinity to their respective antigen, functional activity, thermostability, electric charge and expression yields. Three previously described framework shuffled, humanized versions of another mouse anti-human EphA2 antibody (mAb B233) were similarly characterized. We show that several of these parameters were either maintained or improved in all humanized molecules when compared with their respective chimaeric counterpart. Therefore, this humanization approach is generally applicable to non-human IgGs and allows for the specific selection of antibodies and antibody fragments exhibiting favorable functional, biochemical and biophysical properties. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3049 / 3060
页数:12
相关论文
共 54 条
[21]   Lowering of pI by acylation improves the renal uptake of 99mTc-labeled anti-Tac dsFv:: effect of different acylating reagents [J].
Kim, I ;
Kobayashi, H ;
Yoo, TM ;
Kim, MK ;
Le, N ;
Han, ES ;
Wang, QC ;
Pastan, I ;
Carrasquillo, JA ;
Paik, CH .
NUCLEAR MEDICINE AND BIOLOGY, 2002, 29 (08) :795-801
[22]  
Kim SJ, 2005, MOL CELLS, V20, P17
[23]  
Klee GG, 2000, ARCH PATHOL LAB MED, V124, P921
[24]   ENGINEERED TURNS OF A RECOMBINANT ANTIBODY IMPROVE ITS IN-VIVO FOLDING [J].
KNAPPIK, A ;
PLUCKTHUN, A .
PROTEIN ENGINEERING, 1995, 8 (01) :81-89
[25]   Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment [J].
Krauss, J ;
Arndt, MAE ;
Martin, ACR ;
Liu, HT ;
Rybak, SM .
PROTEIN ENGINEERING, 2003, 16 (10) :753-759
[26]   Receptor tyrosine kinase EphB4 is a survival factor in breast cancer [J].
Kumar, S. Ram ;
Singh, Jasbir ;
Xia, Guangbin ;
Krasnoperov, Valery ;
Hassanieh, Loubna ;
Ley, Eric J. ;
Scehnet, Jeffrey ;
Kumar, Neil G. ;
Hawes, Debra ;
Press, Michael F. ;
Weaver, Fred A. ;
Gill, Parkash S. .
AMERICAN JOURNAL OF PATHOLOGY, 2006, 169 (01) :279-293
[27]   WILL IMMUNOGENICITY LIMIT THE USE, EFFICACY, AND FUTURE-DEVELOPMENT OF THERAPEUTIC MONOCLONAL-ANTIBODIES [J].
KUUSREICHEL, K ;
GRAUER, LS ;
KARAVODIN, LM ;
KNOTT, C ;
KRUSEMEIER, M ;
KAY, NE .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1994, 1 (04) :365-372
[28]   STABILITY OF PROTEIN PHARMACEUTICALS [J].
MANNING, MC ;
PATEL, K ;
BORCHARDT, RT .
PHARMACEUTICAL RESEARCH, 1989, 6 (11) :903-918
[29]   Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: Recovery of antagonistic activity [J].
Mateo, C ;
Moreno, E ;
Amour, K ;
Lombardero, J ;
Harris, W ;
Perez, R .
IMMUNOTECHNOLOGY, 1997, 3 (01) :71-81
[30]  
Onda M, 1999, J IMMUNOL, V163, P6072